Qiagen (NSDQ: QGEN) expects its China revenues to double this year, riding a wave of demand for its core sample and assay technologies. Last year, Qiagen experienced a 90% increase in China sales, leading the company’s Asia Pacific region to a 40% gain, according to the head of the Asia Pacific division, Victor Shi.
Qiagen provides technologies that are used to isolate DNA, RNA, and proteins from any biological sample. Its assay technologies make specific target biomolecules, such as the DNA of a specific virus, visible for subsequent analysis.
After getting a late start in China – it was not active in the PRC until 2005 – Qiagen is making up for lost time. Not only does it provide standard tools to researchers in the PRC, its China R&D operation also tailors molecular diagnostic tools for China’s unique disease patterns and healthcare needs. At the same time, Qiagen works to make these products affordable in China’s market.
The company has production facilities in Shenzhen and Beijing.
In January of this year, Qiagen formed a partnership with WuXi PharmaTech (NYSE: WX) that will focus on molecular biomarker development (see story). QiagenN will contribute a portfolio of instruments, training, and consumables that WuXi PharmaTech will use in its Shanghai laboratory, expanding its service offerings to its clients. WuXi will also help Qiagen to develop biomarkers, assay panels, personalized healthcare diagnostics, and other products that Qiagen will market.
Disclosure: none.
This article is tagged with: Healthcare
